<DOC>
	<DOCNO>NCT01568580</DOCNO>
	<brief_summary>The purpose study study evaluation efficacy safety GreenGene ( Recombinant Factor VIII ) .</brief_summary>
	<brief_title>Efficacy Safety Recombinant Factor VIII ( GreenGene ) Patients With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Hemophilia A patient least 12 year age At least 150 treatment exposuredays previous FVIII product FVIII≤2 % screen diagnosis ( FVIII≤1 % PK study ) CD4 Lympocyte cell count &gt; 400/㎕ Patients willing cooperate study Patient 's legal guardian 's consent participate study FVIII inhibitor ( neutralize antibody FVIII ) ≥0.6 Bethesda Units Coagulation disorder hemophilia A ( e.g . Idiopathic Thrombocytopenic Purpura , von Willebrand Disease ) Platelet count≤100,000㎣ Subjects clinical evidence symptomatic HIV disease regardless HIVseroposive/seronegative Subjects rFVIII antibody , mouse IgG antibody , CHO antibody Creatinine level 2 time reference rage , GOT GPT level 3 time reference range , diabetes mellitus metabolic disorder Subjects diastolic blood pressure≥100mmHg control antihypertensive medication Anemia ( hemoglobin &lt; 12g/dL ) Subjects severe lifethreatening bleed entry trial Subjects history treatment failure due formation inhibitor FVIII Subjects history severe hypersensitive reaction FVIII concentrate Subjects require premedication FVIII infusion ( e.g . antihistamine , etc )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Recombinant</keyword>
</DOC>